

This article was downloaded by: [Malmo Hogskola]

On: 19 December 2011, At: 23:32

Publisher: Taylor & Francis

Informa Ltd Registered in England and Wales Registered Number: 1072954 Registered office: Mortimer House, 37-41 Mortimer Street, London W1T 3JH, UK



Journal of Asian Natural Products Research

Publication details, including instructions for authors and subscription information:

<http://www.tandfonline.com/loi/ganp20>

Two new sesquiterpene lactone glycosides from *Artemisia frigida* Willd.

Qing-Hu Wang^{a,b}, Yi Sha^a, Wu-Li-Ji Ao^b, Xiu-Lan Wang^b, Xiao-Hua Bao^b, Wen Li^a & Jin-Hui Wang^{a,c}

^a School of Traditional Chinese Materia Medica, Shenyang Pharmaceutical University, Shenyang, 110016, China

^b College of Traditional Mongolian Medicine, Inner Mongolia University for Nationalities, Tongliao, 028000, China

^c Key Laboratory of Structure-based Drug Design & Discovery of Ministry of Education, Shenyang Pharmaceutical University, Shenyang, 110016, China

Available online: 22 Jun 2011

To cite this article: Qing-Hu Wang, Yi Sha, Wu-Li-Ji Ao, Xiu-Lan Wang, Xiao-Hua Bao, Wen Li & Jin-Hui Wang (2011): Two new sesquiterpene lactone glycosides from *Artemisia frigida* Willd., *Journal of Asian Natural Products Research*, 13:7, 645-651

To link to this article: <http://dx.doi.org/10.1080/10286020.2011.584309>

PLEASE SCROLL DOWN FOR ARTICLE

Full terms and conditions of use: <http://www.tandfonline.com/page/terms-and-conditions>

This article may be used for research, teaching, and private study purposes. Any substantial or systematic reproduction, redistribution, reselling, loan, sub-licensing, systematic supply, or distribution in any form to anyone is expressly forbidden.

The publisher does not give any warranty express or implied or make any representation that the contents will be complete or accurate or up to date. The accuracy of any instructions, formulae, and drug doses should be independently verified with primary sources. The publisher shall not be liable for any loss, actions, claims, proceedings, demand, or costs or damages whatsoever or howsoever caused arising directly or indirectly in connection with or arising out of the use of this material.

Two new sesquiterpene lactone glycosides from *Artemisia frigida* Willd.

Qing-Hu Wang^{ab}, Yi Sha^a, Wu-Li-Ji Ao^b, Xiu-Lan Wang^b, Xiao-Hua Bao^b, Wen Li^a and Jin-Hui Wang^{ac*}

^aSchool of Traditional Chinese Materia Medica, Shenyang Pharmaceutical University, Shenyang 110016, China; ^bCollege of Traditional Mongolian Medicine, Inner Mongolia University for Nationalities, Tongliao 028000, China; ^cKey Laboratory of Structure-based Drug Design & Discovery of Ministry of Education, Shenyang Pharmaceutical University, Shenyang 110016, China

(Received 18 February 2011; final version received 24 April 2011)

The investigation of EtOAc-soluble fraction from the aerial parts of *Artemisia frigida* has led to the isolation of two new sesquiterpene lactone glycosides, named as artemofriginoside A and artemofriginoside B. Their structures were characterized as 3 β -(β -D-glucopyranosyloxy)-8 β -(*p*-hydroxyphenylacetyloxy)-4(15),10(14),11(13)-guaiaatrien-1 α ,5 β ,6 β ,7 α H-12,6-olide (**1**) and β -(β -D-glucopyranosyloxy)-8 β -(2-hydroxy-3-methylbutanoyloxy)-4(15),10(14),11(13)-guaiaatrien-1 α ,5 β ,6 β ,7 α H-12,6-olide (**2**), on the basis of 1D and 2D NMR spectral analysis.

Keywords: *Artemisia frigida*; sesquiterpene lactone glycoside; artemofriginoside A; artemofriginoside B

1. Introduction

Artemisia frigida Willd., Agi in Mongolian, is a commonly used medicinal material in Mongolian folk medicine [1–6], distributed throughout Inner Mongolia with occupying 10.38% of its steppe [7]. The aerial parts of *A. frigida* are used as a clinical medicine to treat many diseases, such as hemorrhage, arthrocele, nepropyrexia, rheumatoid, and menoxenia [8–10]. Sesquiterpenoids [11,12], coumarins [13], and flavonoids [14–16] have been reported from *A. frigida*. Recently, we carried out a systematic chemical study on the EtOAc-soluble fraction from the aerial parts of *A. frigida*, which resulted in the isolation of two new sesquiterpene lactone glycosides. This study is concerned with the isolation and structural elucidation of two new sesquiterpene lactone glycosides, artemofriginoside A (**1**) and artemofriginoside B (**2**).

2. Results and discussion

The 95% ethanol extract of *A. frigida* was suspended in water and then partitioned with petroleum ether (PE), CHCl₃, EtOAc, and *n*-BuOH. The EtOAc-soluble fraction was separated by chromatography and two new sesquiterpene lactone glycosides, 3 β -(β -D-glucopyranosyloxy)-8 β -(*p*-hydroxyphenylacetyloxy)-4(15),10(14),11(13)-guaiaatrien-1 α ,5 β ,6 β ,7 α H-12,6-olide (**1**) and β -(β -D-glucopyranosyloxy)-8 β -(2-hydroxy-3-methylbutanoyloxy)-4(15),10(14),11(13)-guaiaatrien-1 α ,5 β ,6 β ,7 α H-12,6-olide (**2**) were obtained (Figure 1).

Compound **1** was obtained as yellowish solid. It displayed a molecular formula of C₂₉H₃₄O₁₁, as established from HR-ESI-MS at *m/z* 557.2026 [M – H][–] and ¹³C NMR spectrum. The ¹H and ¹³C NMR spectra showed typical signals of an α -methylene- γ -lactone ring at δ _H 6.03 (d,

*Corresponding author. Email: wjh.1972@yahoo.com.cn




Figure 1. Structures of **1** and **2**.

$J = 3.3$ Hz) and 5.44 (d, $J = 3.3$ Hz) and δ_{C} 122.3, 136.3, and 169.0 [17]. The α,β -unsaturated carbonyl resonating at δ 169.0 was assigned to C-12 because it showed HMBC correlations with H-13. The ^1H and ^{13}C NMR spectra also showed typical signals of two exomethylenes at δ_{H} 5.06, 4.77, 5.48, 5.33 and δ_{C} 117.7, 112.5. The carbon signals at δ 150.8 and 112.5 were assigned to C-4 and C-15, respectively, because H₂-15 at δ 5.48 (1H, br s) and 5.33 (1H, br s) showed HMBC correlations with C-4 at δ 150.8 and C-3, H-3 at δ 4.64 (1H, br t, 7.0) showed HMBC correlations with C-4 at δ 150.8 and C-5 at δ 112.5. The anomeric proton at δ 4.46 (1H, d, 7.5) and the anomeric carbon at δ 103.9 were observed in the ^1H and ^{13}C NMR spectra of **1**. By analysis of the ^1H NMR, ^{13}C

NMR, HMQC, and HMBC spectra of **1**, **1** was deduced to be a sesquiterpene lactone glycoside. In the NOESY spectrum of **1**, the correlation signals were observed obviously at H-5/H-6 β and H-1/H-7 α , and thus the configurations of H-5 and H-1 were determined as β and α , respectively. Furthermore, the coupling constant of $J_{\text{H-6}/\text{H-7}}$ (9.3 Hz) showed the presence of the A,B *trans*-fused guaianolide skeleton with *trans*-diaxial disposition of H-6 and H-7 [18]. The strong NOESY correlations between H-8 and H-7 α as well as between H-3 and H-7 α confirmed the α -configurations of both H-8 and H-3. The presence of 4-hydroxyphenylacetic acid ester was evident from the aromatic A₂B₂ signals at δ 7.00, 6.70 (each 2H, d, $J = 8.4$ Hz) and a benzylic methylene singlet at δ 3.46 [18].

Three oxygenated methines observed at δ 4.64 (1H, br t, 7.0), 4.46 (1H, br t, 9.3), and 5.49 (1H, ddd, 4.8, 2.5, 2.0) were assigned to H-3, H-6, and H-8, respectively. The relative downfield shift of H-8 (δ 5.49) was attributed to the attachment of the ester moiety that was proved by HMBC correlation (Figure 2) between H-8 and the ester carbonyl at δ 172.9. The anomeric proton at δ 4.46 (d, $J = 7.5$ Hz) showed $^1\text{H}-^{13}\text{C}$ long-range correlation with C-3 at δ 81.5, indicating that the glucopyranosyloxy moiety was linked to C-3 position. The β -anomeric configuration for the glucose was determined from their large $^3J_{\text{H}_{1,\text{H}_2}}$ coupling constants ($J = 7.5$ Hz). Therefore, the structure of **1** was elucidated as 3 β -(β -D-glucopyranosyloxy)-8 β -(*p*-hydroxyphenylacetyloxy)-4(15),10(14),

11(13)-guaianatrien-1 α ,5 β ,6 β ,7 α H-12,6-olide (**1**), named as artemofriginoside A. Some key correlations of HMBC and NOESY were shown in Figures 2 and 3.

Compound **2** was obtained as yellowish solid. The molecular formula of **2** was deduced to be $\text{C}_{26}\text{H}_{36}\text{O}_{11}$ on the basis of its HR-ESI-MS data at m/z 523.2161 $[\text{M} - \text{H}]^-$ and ^{13}C NMR spectrum. The IR and NMR spectra revealed the presence of α -methylene- γ -lactone ring and a β -D-glucosyl moiety similar to that of **1**. The ^1H NMR spectrum of **2** was similar to that of **1** except for the absence of the aromatic A_2B_2 signals at δ 7.00, 6.70 (each 2H, d, $J = 8.4$ Hz) and a benzylic methylene singlet at δ 3.46, and the appearance of two methyl signals at δ 0.95 (3H, d, $J = 6.0$ Hz) and 0.88 (3H, d, $J = 6.0$ Hz). The ^{13}C NMR




Figure 2. Some key HMBC correlations of **1** and **2**.




Figure 3. Some key NOESY correlations of **1** and **2**.

spectral data (Table 1) of **2** were also similar to those of **1**, but five additional signals at δ 17.1, 19.3, 33.1, 76.6, and 174.6 were observed. The five signals were the characteristic carbon signals of the 2-hydroxy-3-methylbutanoyloxy unit. In the ^1H NMR spectrum, the characteristic proton signals of the 2-hydroxy-3-methylbutanoyloxy unit at δ 3.88 (1H, m), 1.98 (1H, m), 0.95 (3H, d, 6.0), 0.88 (3H, d, 6.0) were also observed. The signals of C-7 and C-9 were shifted upfield to δ 49.8, 41.0, and that of C-8 was shifted downfield to δ 69.8, respectively. Thus, compound **2** was assumed to have a C₅ unit ester group at C-8. The HMBC correlations between H-8, H-2', and C-1' suggested that the 2-hydroxy-3-

methylbutanoyloxy was located at C-8 position. The strong NOESY correlations between H-8 and H-7 α as well as between H-3 and H-7 α confirmed the α -configuration of both H-8 and H-3. The anomeric proton signal of D-glucosyl moiety at δ 4.46 (1H, d, 7.5) and the anomeric carbon at δ 104.3 were observed in the ^1H and ^{13}C NMR spectra of **2**. The β -anomeric configurations for the glucose were determined from their large $^3J_{\text{H}_1, \text{H}_2}$ coupling constants ($J = 7.5$). In the HMBC spectrum, the cross-peaks between the anomeric proton signal and the carbon signal at δ 81.6 indicated that the glucopyranosyloxy moiety was linked to C-3 position. Therefore, the structure of **2** was elucidated as β -(β -D-glucopyrano-

Table 1. ^1H (600 MHz) and ^{13}C (150 MHz) NMR spectral data for **1** and **2** in CD_3OD .

1			2		
No.	δ_{C}	δ_{H} (J in Hz)	No.	δ_{C}	δ_{H} (J in Hz)
1	45.3	2.95 (1H, br t, 9.3)	1	45.7	3.03 (1H, br t, 9.9)
2	38.5	2.43 (1H, m), 1.98 (1H, m)	2	38.7	2.41 (1H, m), 2.02 (1H, m)
3	81.5	4.64 (1H, br t, 7.0)	3	81.6	4.64 (1H, br t, 9.9)
4	150.8		4	151.0	
5	51.0	2.80 (1H, br t, 9.3)	5	51.4	2.86 (1H, br t, 9.9)
6	80.2	4.46 (1H, br t, 9.3)	6	80.3	4.64 (1H, br t, 9.9)
7	49.0	3.34 (1H, m)	7	49.8	3.34 (1H, m)
8	69.3	5.49 (1H, ddd, 4.8, 2.5, 2.0)	8	69.8	5.64 (1H, ddd, 5.0, 3.0, 2.0)
9	41.4	2.65 (1H, m), 2.52 (1H, m)	9	41.0	2.62 (1H, m), 2.52 (1H, m)
10	144.4		10	144.6	
11	136.3		11	136.9	
12	169.0		12	171.3	
13	122.3	6.03 (1H, d, 3.3), 5.44 (1H, d, 3.3)	13	122.4	6.21 (1H, d, 3.3), 5.61 (1H, d, 3.3)
14	117.7	5.06 (1H, br s), 4.77 (1H, br s)	14	118.0	5.16 (1H, br s), 4.95 (1H, br s)
15	112.5	5.48 (1H, br s), 5.33 (1H, br s)	15	113.0	5.48 (1H, br s), 5.38 (1H, br s)
1'	172.9		1'	174.6	
2'	40.0	3.46 (2H, s)	2'	76.6	3.88 (1H, m)
3'	126.1		3'	33.1	1.98 (1H, m)
4'	116.3	7.00 (1H, d, 8.4)	4'	19.3	0.95 (3H, d, 6.0)
5'	131.4	6.70 (1H, d, 8.4)	5'	17.1	0.88 (3H, d, 6.0)
6'	157.6				
7'	131.4	6.70 (1H, d, 8.4)			
8'	116.3	7.00 (1H, d, 8.4)			
1''	103.9	4.46 (1H, d, 7.5)	1''	104.3	4.46 (1H, d, 7.5)
2''	75.3	3.18 (1H, dd, 8.9, 7.5)	2''	75.1	3.18 (1H, dd, 8.9, 7.5)
3''	78.1	3.42 (1H, m)	3''	78.1	3.34 (1H, m)
4''	71.7	3.30 (1H, m)	4''	71.7	3.30 (1H, m)
5''	77.9	3.71 (1H, dd, 9.3, 4.5)	5''	77.9	3.40 (1H, dd, 9.0, 4.4)
6''	62.8	3.85 (1H, m), 3.68 (1H, m)	6''	62.8	3.86 (1H, m), 3.68 (1H, m)

syloxy)-8 β -(2-hydroxy-3-methylbutanoyloxy)-4(15),10(14),11(13)-guaia-trien-1 α ,5 β ,6 β ,7 α H-12, 6-olide (**2**), named as artemofriginoside B. Some key correlations of HMBC and NOESY were shown in Figures 2 and 3.

3. Experimental

3.1 General experimental procedures

Optical rotations were measured in MeOH at 25°C on a PerkinElmer 241 polarimeter. The IR spectra were recorded in KBr discs on a Thermo Nicolet 200 double beam spectrophotometer. NMR spectra were

measured on a Bruker ARX-600 NMR spectrometer with tetramethylsilane (TMS) as the internal reference, and chemical shifts are expressed in δ (ppm). The HR-ESI-MS spectra were measured on a Bruker Daltonics MicrOTOF-Q. Semipreparative HPLC was performed using a Japanese liquid chromatograph equipped with a Zorbax SB-C18 column. Column chromatography was performed using silica gel (200–300 mesh, Marine Chemical Factory, Qingdao, China) and Sephadex LH-20 (Pharmacia, Uppsala, Sweden). Fractions were monitored by TLC (silica gel GF₂₅₄ 10–40 μm , Marine Chemical Factory,

Qingdao, China), and spots were visualized by heating silica gel plates sprayed with 10% H₂SO₄ in EtOH.

3.2 Plant material

The aerial parts of *A. frigida*, used as experimental material, were collected in Tongliao, Inner Mongolia of China, in July 2007, and identified by Prof. Buhebateer (Inner Mongolia University for Nationalities). A voucher (No. 20070720) has been deposited in the School of Traditional Mongolian Medicine of Inner Mongolia University for Nationalities.

3.3 Extraction and isolation

The air-dried aerial parts of *A. frigida* (2 kg) were crushed and extracted twice under reflux 95% EtOH. Evaporation of the solvent under reduced pressure delivered the 95% EtOH extract. The extract was partitioned with PE, CHCl₃, EtOAc, and *n*-BuOH. The EtOAc-soluble fraction (30.0 g) was isolated by column chromatography on silica gel and gradiently eluted with CHCl₃–acetone (80:1 to 5:1) to give 20 fractions (1–20). Fraction 6 [400 mg, CHCl₃–acetone (30:1) eluate] was loaded onto a column of silica gel and eluted with CHCl₃–acetone (50:1 to 1:1) to give seven fractions (6-1 to 6-7). Fraction 6-4 (60 mg) was further purified by column chromatography on silica gel with CHCl₃–acetone (20:1) to give **1** (12 mg) and **2** (10 mg).

3.3.1 3β-(β-D-Glucopyranosyloxy)-8β-(p-hydroxyphenylacetyloxy)-4(15),10(14),11(13)-guaiatrien-1α,5β,6β,7αH-12,6-olide (**1**)

Yellowish solid; $[\alpha]_D -20.4$ ($c = 0.1$, MeOH); IR (KBr) ν_{\max} (cm⁻¹): 3550, 1760, 1740, 1660, 1640; ¹H and ¹³C NMR spectral data: Table 1; HR-ESI-MS: m/z 557.2026 [M – H]⁻ (calcd for C₂₉H₃₃O₁₁, 557.2023).

3.3.2 3β-(β-D-glucopyranosyloxy)-8β-(2-hydroxy-3-methylbutanoyloxy)-4(15),10(14),11(13)-guaiatrien-1α,5β,6β,7αH-12,6-olide (**2**)

Yellowish solid; $[\alpha]_D -19.6$ ($c = 0.1$, MeOH); IR (KBr) ν_{\max} (cm⁻¹): 3402, 1768, 1735, 1515, 1245; ¹H and ¹³C NMR spectral data: Table 1; HR-ESI-MS: m/z 523.2161 [M – H]⁻ (calcd for C₂₆H₃₅O₁₁, 523.2179).

Acknowledgements

This work was financially supported by National Major Special Science and Technology Project (2010ZX09401-304-104A). We are grateful to Prof. Buhebateer for the identification of the plant material.

References

- [1] Hasibagen, Yi Zong Yao Zhi (Inner Mongolia People's Press, Huhehaote, 1999), p. 499.
- [2] W.D.M. Zao, *Compilation of Prescription for the Traditional Mongolian Medicine* (Inner Mongolia Science and Technology Press, Chifeng, 2004), p. 122.
- [3] Jigemudedan, and Jinzamusu, *Tong Wa Ga Ji De* (Inner Mongolia People's Press, Huhehaote, 1999), p. 219.
- [4] B. Jin, *Lin Zheng Yi Yao Jian* (Inner Mongolia People's Press, Huhehaote, 1977), p. 899.
- [5] Guanqigerupanwangbu, *Zhe Dui Pan De Ning Bu* (Inner Mongolia People's Press, Huhehaote, 1987), p. 80.
- [6] Namujila, *Aoteqi 5 of Mongolian People* (Inner Mongolia Children Press, Huhehaote, 1993), p. 68.
- [7] Y. Liu, J.G. Liu, and L. Tang, *Stud. Trace Elements Health* **25**, 55 (2008).
- [8] Q.Y. Bai, *Chinese Medical Encyclopaedia-Mongolian Medicine* (Inner Mongolia Science and Technology Press, Chifeng, 1986), p. 322.
- [9] Zambula, and Daoerji, *Meng Yao Zheng Dian* (Inner Mongolia People's Press, Huhehaote, 1984), p. 260.
- [10] M.G. Nei, *Standard of Traditional Mongolian Medical Material* (Inner Mongolia Science and Technology Press, Chifeng, 1987), p. 342.
- [11] Y.L. Liu and T.J. Mabry, *J. Nat. Prod.* **44**, 722 (1981).

- [12] Y.L. Liu and T.J. Mabry, *J. Nat. Prod.* **24**, 1009 (1985).
- [13] H. Greger, P. Hofer, and W. Robian, *Phytochemistry* **22**, 1997 (1983).
- [14] Y.L. Liu and T.J. Mabry, *Phytochemistry* **20**, 309 (1981).
- [15] Y.L. Liu and T.J. Mabry, *Phytochemistry* **20**, 189 (1981).
- [16] Q.H. Wang and J.H. Wang, *Chin. Tradit. Herb. Drugs* **40**, 1540 (2009).
- [17] H. Asada, T. Miyase, and S. Fukushima, *Chem. Pharm. Bull.* **32**, 3036 (1984).
- [18] A.M. Helal, N. Nakamura, M.R. Meselhy, A.M. El-Fishawy, M. Hattori, and G.H. Mahran, *Phytochemistry* **45**, 551 (1997).